Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Eligo Bioscience

Main focus: Treatment of bacterial infections

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR-Cas

Funding stage: Private

Location: Paris, France


Gene editing partnerships: GlaxoSmithKline

Eligo Biosciences seeks to perform precision editing of the human microbiome in order to treat infectious diseases. The company develops engineered phages that deliver CRISPR-Cas systems to pathogenic bacteria. The company has not yet disclosed its lead development programmes, but announced a research and option agreement with GlaxoSmithKline to advance new development candidates from its technology platform.


HashtagEligo Bioscience

Company: Eligo Bioscience
Search CRISPR Medicine